Dr. William Hall awards the first annual “Caroline B. Hall Young Investigator Award” to Dr. Yoshiki Kawamura of Japan.
Mothers with ciHHV-6 can produce active virus, transmit to children transplacentally
New findings suggest that ciHHV-6 can be reactivated and then acquired transplacentally.
NIH Laboratory develops novel marmoset model of HHV-6A & HHV-6B infection
Dr. Steven Jacobson’s laboratory at the US National Institute of Health has developed a novel marmoset model for the study of HHV-6 infection.
Role for HHV-6 in patients with renal failure?
A new study from Brazil indicates that active HHV-6 infection may play a role in patients with renal failure prior to transplantation.
New study shows that HHV-6 encephalitis leads to very poor outcome
New study shows that patients who develop HHV-6 encephalitis have a significantly poor prognosis
Herpesvirus foundation established in Zambia, studies HHV-6A & HHV-6B
Nonprofit dedicated to promoting herpesvirus research in Zambia and across sub-Saharan Africa.
Why does HHV-6 reactivate preferentially in CBT?
A group from France has reported new findings which may help explain the mystery behind the increased rates of HHV-6 reactivation and encephalitis observed among umbilical cord blood transplant (CBT) patients.
Bortezomib may increase risk of HHV-6 reactivation in myeloma patients
A new study has reported that the use of Bortezomib, known commercially as Velcade, may increase the risk of HHV-6 reactivation in myeloma patients undergoing stem cell transplantation.
Funding gap! HHV-6 & HHV-7 have received only a fraction of the funding received by EBV, CMV and HHV-8.
Since 2000, NIH has given nearly $1 Billion in total grant funding to study the herpesviruses EBV, CMV, and KSHV, compared to only $15 million to study HHV-6 & HHV-7.
Increased prevalence of HHV-6 antibodies discovered in multiple sclerosis patients
An increased prevalence of HHV-6 U94/REP antibodies found among Tunisian MS patients.
High rate of active HHV-6 detected among patients with cardiac disease
Unusually high rate of active HHV-6 infection detected among hospital patients with cardiac disease.
CMX001 shows strong in-vitro activity against HHV-6
Data from a recent report may increasingly argue in favor of using the antiviral known as CMX001 for treatment of HHV-6 infection.
New HHV-6 species-specific serological assay developed
This new assay will hopefully open the door for increased exploration into the seroepidemiology of HHV-6A and HHV-6B infection.
In Memoriam- Caroline B. Hall Young Investigator Award
The HHV-6 Foundation has established an award in memory and honor of Dr. Caroline Breese Hall, a renowned Pediatric Infectious Diseases physician and expert on HHV-6 who passed away in December 2012.
Further characterization of HHV-6B immune response leads to development of virus-specific immunotherapy
A group from Baylor has further characterized the clinical HHV-6B immune response, and is using this new information to develop an enhanced adoptive T cell immunotherapy specific to HHV-6 for HSCT patients.